PDF herunterladen
Am J Perinatol 2022; 39(09): 0959-0964
DOI: 10.1055/s-0040-1721132
Original Article

Birth Weight Standard Deviation Score is a Significant Determinant of Serum Urotensin-II Levels at Term-Equivalent Age in Preterm Infants

Akio Ebata
1   Department of Pediatrics, Showa University School of Medicine, Tokyo, Japan
,
Yuya Nakano
1   Department of Pediatrics, Showa University School of Medicine, Tokyo, Japan
,
Gakuto Ujiie
1   Department of Pediatrics, Showa University School of Medicine, Tokyo, Japan
,
Yoko Ishii
1   Department of Pediatrics, Showa University School of Medicine, Tokyo, Japan
,
Takeshi Shimizu
2   Pediatric Heart Disease and Adult Congenital Heart Disease Center, Showa University Hospital, Tokyo, Japan
,
Takanari Fujii
2   Pediatric Heart Disease and Adult Congenital Heart Disease Center, Showa University Hospital, Tokyo, Japan
,
Katsumi Mizuno
› Institutsangaben Funding This work was supported by a grant from the Morinaga Foundation for Health & Nutrition.
› Weitere Informationen
    Lizenzen und Reprints

Abstract

Objective Urotensin II (U-II) is a potent vasoconstrictor peptide, and increased U-II levels are associated with atherosclerosis and hypertension in adults. Low birth weight (LBW) infants have higher risks of such diseases in the future. A small number of nephrons is one of possible mechanism underlying these risks in LBW infants, while vascular elasticity and cardiac function might be another important factor. The objective of this study is to evaluate U-II levels in preterm LBW infants at an early stage of life and determine perinatal factors associated with U-II levels.

Study Design The study population consisted of 57 preterm LBW infants (26 males and 31 females), including 49 appropriate for gestational age (AGA) and 8 small for gestational age (SGA) infants, born at a gestational age of ≤34 weeks with a mean birth weight of 1,589 g. Serum U-II levels were measured at term-equivalent age to evaluate perinatal factors related to serum U-II levels.

Results Preterm SGA infants had significantly higher serum U-II levels than preterm AGA infants at term-equivalent age (p = 0.019). Serum U-II levels in preterm LBW infants at term-equivalent age were inversely correlated with birth weight standard deviation (SD) score in a simple regression analysis (r =  − 0.395, p = 0,002) and the correlation was maintained in the multiple regression analysis.

Conclusion Our results indicate that birth weight SD score might be associated with serum U-II levels in preterm LBW infants at term-equivalent age. Further studies are required to determine whether U-II levels at an early stage of life might influence the risk of atherosclerosis and hypertension.

Key Points

  • U-II is a potent vasoconstrictor.

  • We evaluated serum U-II levels in preterm infants.

  • Fetal growth is negatively related to serum U-II levels.

Keywords

atherosclerosis - birth weight SD score - hypertension - low birth weight infants - preterm infants - small for gestational age - urotensin II


Publikationsverlauf

Eingereicht: 04. Dezember 2020

Angenommen: 16. Oktober 2020

Artikel online veröffentlicht:
26. November 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Barker DJP, Osmond C, Golding J, Kuh D, Wadsworth MEJ. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ 1989; 298 (6673): 564-567
    CrossrefPubMedGoogle Scholar
  • 2 de Jong F, Monuteaux MC, van Elburg RM, Gillman MW, Belfort MB. Systematic review and meta-analysis of preterm birth and later systolic blood pressure. Hypertension 2012; 59 (02) 226-234
    CrossrefPubMedGoogle Scholar
  • 3 Luyckx VA, Bertram JF, Brenner BM. et al. Effect of fetal and child health on kidney development and long-term risk of hypertension and kidney disease. Lancet 2013; 382 (9888): 273-283
    CrossrefPubMedGoogle Scholar
  • 4 Baum M. Role of the kidney in the prenatal and early postnatal programming of hypertension. Am J Physiol Renal Physiol 2010; 298 (02) F235-F247
    CrossrefPubMedGoogle Scholar
  • 5 Pearson D, Shively JE, Clark BR. et al. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci U S A 1980; 77 (08) 5021-5024
    CrossrefPubMedGoogle Scholar
  • 6 McDonald J, Batuwangala M, Lambert DG. Role of urotensin II and its receptor in health and disease. J Anesth 2007; 21 (03) 378-389
    CrossrefPubMedGoogle Scholar
  • 7 Russell FD, Molenaar P, O'Brien DM. Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 2001; 132 (01) 5-9
    CrossrefPubMedGoogle Scholar
  • 8 Watanabe T, Kanome T, Miyazaki A, Katagiri T. Human urotensin II as a link between hypertension and coronary artery disease. Hypertens Res 2006; 29 (06) 375-387
    CrossrefPubMedGoogle Scholar
  • 9 Ames RS, Sarau HM, Chambers JK. et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999; 401 (6750): 282-286
    CrossrefPubMedGoogle Scholar
  • 10 Loirand G, Rolli-Derkinderen M, Pacaud P. Urotensin II and atherosclerosis. Peptides 2008; 29 (05) 778-782
    CrossrefPubMedGoogle Scholar
  • 11 Xu J, Han Q, Shi H, Liu W, Chu T, Li H. Role of PKA in the process of neonatal cardiomyocyte hypertrophy induced by urotensin II. Int J Mol Med 2017; 40 (02) 499-504
    CrossrefPubMedGoogle Scholar
  • 12 Sun SL, Liu LM. Urotensin II: an inflammatory cytokine. J Endocrinol 2019; 240: R107-R117
    CrossrefPubMedGoogle Scholar
  • 13 Cheung BM, Leung R, Man YB, Wong LY. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 2004; 22 (07) 1341-1344
    CrossrefPubMedGoogle Scholar
  • 14 Peng H, Zhang M, Cai X, Olofindayo J, Tan A, Zhang Y. Association between human urotensin II and essential hypertension--a 1:1 matched case-control study. PLoS One 2013; 8 (12) e81764
    CrossrefPubMedGoogle Scholar
  • 15 Ng LL, Loke I, O'Brien RJ, Squire IB, Davies JE. Plasma urotensin in human systolic heart failure. Circulation 2002; 106 (23) 2877-2880
    CrossrefPubMedGoogle Scholar
  • 16 Thompson JP, Watt P, Sanghavi S, Strupish JW, Lambert DG. A comparison of cerebrospinal fluid and plasma urotensin II concentrations in normotensive and hypertensive patients undergoing urological surgery during spinal anesthesia: a pilot study. Anesth Analg 2003; 97 (05) 1501-1503
    CrossrefPubMedGoogle Scholar
  • 17 Mosenkis A, Kallem RR, Danoff TM, Aiyar N, Bazeley J, Townsend RR. Renal impairment, hypertension and plasma urotensin II. Nephrol Dial Transplant 2011; 26 (02) 609-614
    CrossrefPubMedGoogle Scholar
  • 18 Pawar R, Kemp W, Roberts S, Krum H, Yandle T, Hardikar W. Urotensin II levels are an important marker for the severity of portal hypertension in children. J Pediatr Gastroenterol Nutr 2011; 53 (01) 88-92
    CrossrefPubMedGoogle Scholar
  • 19 Huang CY, Burns JC, Shimizu C. Urotensin 2 in Kawasaki disease pathogenesis. Pediatr Res 2017; 82 (06) 1048-1055
    CrossrefPubMedGoogle Scholar
  • 20 Simpson CM, Penny DJ, Stocker CF, Shekerdemian LS. Urotensin II is raised in children with congenital heart disease. Heart 2006; 92 (07) 983-984
    CrossrefPubMedGoogle Scholar
  • 21 Edvardsson VO, Steinthorsdottir SD, Eliasdottir SB, Indridason OS, Palsson R. Birth weight and childhood blood pressure. Curr Hypertens Rep 2012; 14 (06) 596-602
    CrossrefPubMedGoogle Scholar
  • 22 Iwashima S, Ishikawa T, Akira O, Itou H. Association of abdominal aortic wall thickness in the newborn with maternal factors. Am J Perinatol 2012; 29 (06) 441-448
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 23 Zanardo V, Visentin S, Trevisanuto D, Bertin M, Cavallin F, Cosmi E. Fetal aortic wall thickness: a marker of hypertension in IUGR children?. Hypertens Res 2013; 36 (05) 440-443
    CrossrefPubMedGoogle Scholar
  • 24 Nakano Y, Itabashi K, Sakurai M, Aizawa M, Dobashi K, Mizuno K. Preterm infants have altered adiponectin levels at term-equivalent age even if they do not present with extrauterine growth restriction. Horm Res Paediatr 2013; 80 (03) 147-153
    CrossrefPubMedGoogle Scholar
  • 25 Itabashi K. Standard values of birth weight, length, and head circumstances at birth. (in Japanese). Perinat Med (Tokyo) 2010; 40 (special issue): 943-960
    PubMedGoogle Scholar
  • 26 Barrette PO, Schwertani AG. A closer look at the role of urotensin II in the metabolic syndrome. Front Endocrinol (Lausanne) 2012; 3: 165
    CrossrefPubMedGoogle Scholar
  • 27 Maguire JJ, Kuc RE, Wiley KE, Kleinz MJ, Davenport AP. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 2004; 25 (10) 1767-1774
    CrossrefPubMedGoogle Scholar
  • 28 Zhao S, Li Y, Gao S. et al. Autocrine human urotensin II enhances macrophage-derived foam cell formation in transgenetic rabbits. BioMed Res Int 2015; 2015: 843959
    CrossrefPubMedGoogle Scholar
  • 29 Leipälä JA, Boldt T, Turpeinen U, Vuolteenaho O, Fellman V. Cardiac hypertrophy and altered hemodynamic adaptation in growth-restricted preterm infants. Pediatr Res 2003; 53 (06) 989-993
    CrossrefPubMedGoogle Scholar
  • 30 Sehgal A, Doctor T, Menahem S. Cardiac function and arterial biophysical properties in small for gestational age infants: postnatal manifestations of fetal programming. J Pediatr 2013; 163 (05) 1296-1300
    CrossrefPubMedGoogle Scholar
  • 31 Kandasamy Y, Smith R, Wright IM, Lumbers ER. Relationships between glomerular filtration rate and kidney volume in low-birth-weight neonates. J Nephrol 2013; 26 (05) 894-898
    CrossrefPubMedGoogle Scholar
  • 32 Aljunaidy MM, Morton JS, Cooke CM, Davidge ST. Prenatal hypoxia and placental oxidative stress: linkages to developmental origins of cardiovascular disease. Am J Physiol Regul Integr Comp Physiol 2017; 313 (04) R395-R399
    CrossrefPubMedGoogle Scholar